Vancouver-based Forbes Medi-Tech has signed an international supply agreement with Australian firm Pan Pharmaceuticals for Reducol, a cholesterol-lowering phytosterol-based ingredient.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more


The initial supply agreement is for a minimum of three-years, and secures Sydney-based Pan Pharmaceuticals’ exclusive rights to supply Reducol in the form of a dietary supplement to the Australian market, and selected countries in Asia, the Middle East, Africa, as well as three countries in Europe.


“This agreement will give Forbes tremendous exposure in several key
international markets,” said Charles Butt, president and CEO of Forbes Medi-Tech: “Pan Pharmaceuticals has an intimate working knowledge of the cultures, regulatory systems and product preferences in these markets, which makes it an ideal partner for Forbes.”


Reducol is used in dietary supplements in the form of tablets capsules and soft-gel capsules.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Just Food Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Just Food Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving food industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now